India, Nov. 6 -- Sana Biotechnology, Inc. (SANA) reported third-quarter 2026 financial results and business updates, highlighting progress toward clinical studies of its engineered cell therapy programs for type 1 diabetes and non-Hodgkin lymphoma.
The company also reported a cash position of $121.7 million, with its cash runway expected to extend into mid-2027.
Company Profile
Sana Biotechnology is a biotechnology company focused on developing engineered cells as medicines, with programs targeting cell replacement, gene modification and immune-mediated diseases.
Third Quarter FY26 Financial Highlights
For the three months ended September 30, 2026, research and development expenses increased to $33.9 million from $30.1 million in the p...